Zentalis Pharmaceuticals to Participate In Two Upcoming Investor Conferences

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation in two virtual investor conferences featuring CEO Anthony Sun. The first event is the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 5:00 p.m. GMT, where Sun will engage in a fireside chat. The second is the SVB Leerink Oncology 1x1 Day, also on November 19, 2020, focusing on one-on-one meetings. A live webcast of the fireside chat will be accessible on the company's website, alongside an archived version post-event.

NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.

Presentation Details:

Event: Jefferies Virtual London Healthcare Conference
Format: Fireside chat
Date: Thursday, November 19, 2020
Time: 5:00 p.m. GMT/12:00 p.m. EST

Event: SVB Leerink Oncology 1x1 Day
Format: One-on-one meetings
Date: Thursday, November 19, 2020

A live webcast of the Jefferies fireside chat will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the event, an archived webcast will be available on the Zentalis website.

About Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contact:

Thomas Hoffmann

Solebury Trout

1.646.378.2931

thoffmann@soleburytrout.com

Media Contact:

Julia Deutsch

Solebury Trout

1.646.378.2967

jdeutsch@soleburytrout.com

FAQ

What investor conferences is Zentalis Pharmaceuticals participating in on November 19, 2020?

Zentalis Pharmaceuticals is participating in the Jefferies Virtual London Healthcare Conference and the SVB Leerink Oncology 1x1 Day on November 19, 2020.

Who will represent Zentalis at the Jefferies Virtual London Healthcare Conference?

Anthony Sun, the CEO of Zentalis Pharmaceuticals, will represent the company at the Jefferies Virtual London Healthcare Conference.

What time does the Jefferies Virtual London Healthcare Conference take place for ZNTL?

The Jefferies Virtual London Healthcare Conference will take place at 5:00 p.m. GMT/12:00 p.m. EST on November 19, 2020.

How can I access the live webcast for Zentalis Pharmaceuticals' conference?

The live webcast for Zentalis Pharmaceuticals' fireside chat at the Jefferies conference can be accessed through the Investors section of their website.

What is the focus of Zentalis Pharmaceuticals in their drug development?

Zentalis Pharmaceuticals focuses on developing small molecule therapeutics targeting fundamental biological pathways of cancers.